BACKGROUND: Obese patients are often affected by hypertension, dyslipidaemia, impaired glucose metabolism, and suffer from cardiovascular disease (CVD), related to the characteristic metabolic alterations. AIM OF THE STUDY: To evaluate reduction of risk factors for CVDs in morbid-obese patients (body mass index (BMI)440 kg/m 2 ) after weight loss upon bariatric surgery intervention of biliary-intestinal bypass. SUBJECTS: 45 (17 men, 28 women) morbid-obese patients (age: 19-49 y, BMI440 kg/m 2 ). All patients were selected on the basis of medical history, physical and biochemical evaluation and of psychiatric tests, which were performed on all individuals admitted to our Day Hospital to verify the safety of surgical intervention. MEASUREMENTS: Body weight, body composition (by dual X-ray absorptiometry, DXA), blood pressure, lipid profile, fibrinogen and glucose metabolism were monitored at baseline and 1, 3, 6, 9, 12, 24 and 36 months after surgery. RESULTS: A significant and persistent weight loss was present in all patients at the end of the 3 y follow-up period (Po0.001), with a progressive reduction of total and trunk fat mass as evaluated by means of DXA. Additionally, a parallel significant reduction in systolic (Po0.001) and diastolic (Po0.001) blood pressure was observed. Total and LDL cholesterol were significantly reduced (Po0.001), while HDL showed no modifications; triglycerides declined progressively during the 3 y followup (Po0.001). Fibrinogen decreased from 364.5782.4 to 266.4745.7 mg/dl at the end of the period (Po0.001). Fasting glucose levels and glucose levels 120 min after an oral glucose tolerance test were reduced from 95.1720.3 to 78.679.1 mg/dl (Po0.001) and from 116.9734.7 to 77.6715.5 mg/dl (Po0.001), respectively, at baseline and at the end of the study. Moreover, fasting insulin decreased from 30.0720.4 to 8.672.9 mUI/ml (Po0.001) after 3 y, while insulin levels after (120 min) oral glucose load decreased from 105.5761.5 to 12.076.0 mUI/ml (Po0.001). CONCLUSION: Our results show that biliary-intestinal bypass may represent a valid and alternative therapeutic approach in patients with morbid obesity since it induces a significant and stable reduction of body weight and obesity-related risk factors for CVD.
Introduction
Obesity is an increasing health problem in many countries. [1] [2] [3] It is well known that overweight results when energy intake exceeds energy expenditure for a considerable period of time. Striking differences exist in the magnitude of the impact of different obesities on comorbidities. Individuals with peripheral obesity ('pears') possess fat distributed subcutaneously in gluteofemoral areas and the lower part of the abdomen, and are at little risk of metabolic complications. [1] [2] [3] [4] Conversely, individuals with upper-body obesity ('apples') who accumulate fat in subcutaneous and visceral deposits are more prone to metabolic and cardiovascular problems, particularly when visceral fat deposits are abundant. 4 In individuals with body mass index (BMI) greater than 35 kg/m 2 , no distinction between visceral and peripheral obesity is made due to the severe degree of abundant fat deposits. Patients affected by abdominal obesity, often affected by hypertension, dyslipidaemia and impaired glucose metabolism, suffer from cardiovascular disease (CVD) for reasons that are, in part, still unclear. 5 The clustering of impaired glucose metabolism, elevated triglycerides, low HDL cholesterol and abdominal obesity has been variously labelled as, syndrome X, 6 insulin resistance syndrome 7 or metabolic syndrome. 7 Alone, each component of the cluster conveys an increased risk of CVD, but as a combination they become much more powerful and severe. 8 Obese patients show an increased prevalence of hypertension, 9 dyslipidaemia, hyperglycaemia and fibrinogen excess, 10 in addition to CVDs such as coronary heart disease and stroke. [11] [12] [13] Life style modification should be the goal of obesity treatment. 3 However, this approach cannot always obtain good and stable correction of severe obesity. New potential pharmacological approaches to the treatment of obesity have been developed and are utilised. [14] [15] [16] [17] Additionally, when these therapeutical approaches are not successful, surgical intervention has been developed for the treatment of morbid-obese patients (BMI440 kg/m 2 ) or severe obese patients with comorbidities.
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Among the different surgical approaches, biliary-intestinal bypass is a jejunum-ileum bypass with a large gall bladderjejunum anastomosis at the excluded jejunum, which induces a constant reflux of most bile in the defunctionalised intestinal loop.
19-21 Biliary-intestinal bypass represents a good model of massive and rapid weight reduction due to the induced malabsorptive state. Our preliminary studies have demonstrated good compliance by patients who underwent biliary-intestinal bypass with a significant and stable weight reduction. [20] [21] [22] [23] [24] The aim of the present study was to evaluate and to follow up the modifications of cardiovascular risk factors in obese patients (BMI440 kg/m 2 ) upon biliary-intestinal bypass [19] [20] [21] to assess whether it may represent a valid alternative therapeutical approach.
Patients and methods
A total of 45 patients (17 men, 28 women) of age 19-49 y and weight 134.5725.4 kg underwent surgery in our department from 1996 to 2000.
A strictly proteic diet associated with total exclusion of alcohol, soft-drinks and hot foods was proposed for the first month for each patient undergoing biliary-intestinal bypass to avoid side effects such as diarrhoea and meteorism. Additionally, a multivitamin supplement (Mg, Ca, Fe, Zn, Mn, Cu, I, Cr, Se, vitamin A, B 1 , B 2 , B 6 , C, D 3 , E, PP, folic acid and biotin (two effervescent tablets/day), vitamin B 12 (5000 mg i.m./month)) and a further supplementation of the following minerals was also recommended: calcium (2 g/ day), Fe 3 þ (125 mg Â 2/day), K, Mg (40 mg/day). Doses were modified according to blood test results. Body weight and blood pressure were monitored every 3 months during the first year, and every 6 months thereafter until the end of the 3 y follow-up. Lipid profile, glucose and insulin blood levels during fasting and 120 min after an oral glucose tolerance test (OGTT) were evaluated at the same intervals.
Anthropometric measurements included weight, height and BMI, defined as weight (kg)/height 2 (m 2 ), were performed.
Body fat and lean mass were measured by means of dual Xray absorptiometry (DXA) 25 (Hologic 4500 RDR) with coefficient of variation of o1% for bone density and o1.5% for fat mass. However, it was not possible to perform DXA analysis in patients with a body weight over 140 kg. Blood samples were collected and blood pressure was measured in the morning (usually between 0800 and 0900) after an overnight fast.
Total and HDL cholesterol and triglyceride concentrations were measured on fresh serum by automated enzymatic method (Dimension Dade Behring Analyzer and reagent cartridges from Dade Behring Sp.A, Milano, Italy). All samples were assayed in duplicate with intrassay and interassay mean coefficients of variation of 2 and 4%, respectively. LDL was calculated with Friedwalld's formula. Fibrinogen was measured by Clauss method (BCT DadeBehring). A 75 g OGTT was performed in the morning after at least 3 days of unrestricted diet (greater than 150 g of carbohydrate daily) and usual physical activity. The test was preceded by an overnight fast of 8-14 h, during which water access was free. Smoking was not allowed during the test. 26 This test was not executed in diabetic patients treated with oral hypoglycaemic drugs or with a fasting glucose Z126 mg/dl. (No diabetic patient under treatment with insulin underwent biliary-intestinal bypass.) Plasma glucose determinations were performed using the hexokinase method (Aeroset Abbott). Quantitative determination of insulin was performed by radioimmunoassay. According to the American Diabetic Association (ADA) classification criteria for diabetes, a fasting plasma glucose o110 mg/dl was considered normal, while fasting plasma glucose 4110 and o126 mg/dl was considered impaired fasting glucose (IFG). Fasting plasma glucose 4126 mg/dl was labelled as diabetes; 2 h postload glucose o140 mg/dl was labelled as normal tolerance, while 2 h postload glucose Z140 and o200 mg/dl was labelled as impaired glucose tolerance (IGT); and 2 h postload glucose Z200 mg/dl was considered as diabetes. 27 An insulin basal concentration less than 25 mUI/ml was considered normal.
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The blood pressure was measured by a mercury sphygmomanometer (EKRA, Riva-Rocci System). Patients affected by hypertension starting or changing antihypertensive therapy during the weight loss were excluded from this study.
Inclusion criteria were as follows: BMIZ40 kg/m 2 ; primary obesity age 18-55 y; restricted responsiveness to repeated and protracted medical treatment; absence of serious psychopathological problems and/or pharmaceutical or alcohol abuse.
All patients were selected on the basis of medical history, physical and biochemical evaluation and of psychiatric tests, which were performed on all individuals admitted to our Day Hospital to verify the safety of surgical intervention. Eating Disorder Examination (EDE), Body Dismorphic Disorder Examination (BDDE) and other tests referred to general psychopathology were performed at baseline and after 2 y of surgical intervention to evaluate eating behaviour.
In particular, patients were excluded when they presented: (1) severe altered self-body image and belief of immediate resolution of body weight, (2) inability to maintain periodic medical controls and (3) professional activities excluding them from tolerating initial side effects (ie diarrhoea). Instead, biliary-intestinal bypass was indicated in those conditions in which restrictive bariatric surgery was forbidden: binge eating disorder, grazing, night eating, emotional eating.
Statistical analysis
Results are always expressed as mean7standard deviation (M7s.d.) and compared by means of ANOVA for repeated measures and LSD test (planned comparison). Differences were considered statistically different when Po0.05 was found.
Results
A significant and progressive weight loss was observed in all patients during this 3 y follow-up study: mean body weight before surgery was 134.5725.4 kg, while final weight was 85.6714.1 kg (Po0.001) (Figure 1 Table 1) . It is interesting to note that both total and per cent fat, and trunk fat, as measured by DXA, show a significant difference between male and female subjects after weight loss ( Table 2 ). Follow-up of decreased CV risk factors after biliary-intestinal bypass C Lubrano et al
As expected, total lean body mass was reduced, but the difference was not statistically significant (Table 1) . In particular, a significant difference in lean mass between female and male subjects was already present before surgery (Po0.001) and was maintained also at the end of the followup period (Table 2) .
Total, LDL and HDL cholesterol levels were monitored. Total cholesterol levels were quickly blunted from 191.2730.8 to 130.6722.9 mg/dl (Po0.001) at the end of the first month postsurgery. After 3 y, the mean cholesterol level was 114.8734.3 mg/dl (Po0.001 vs baseline) (Table 2, Figure 2) . LDL values also decreased in a parallel manner from 116.0728.8 mg/dl before surgery to 68.7716.6 mg/dl after 3 y (Po0.001) ( Table 1) , while HDL variations during weight loss were not significant. Additionally, triglyceride values decreased in a more progressive manner than cholesterol, but with a percentage decrease similar to that of cholesterol at the end of the follow-up (136.27124.5 to 71.4725.9 mg/dl; Po0.001) (Table 2, Figure 2 ).
We then assessed fibrinogen level at baseline and during the follow-up period. As for the other above-mentioned factors, fibrinogen levels quickly decreased (Table 1) .
At the beginning of the study, systolic and diastolic blood pressure values were 144718 and 9079 mmHg (Table 1) .
They decreased respectively to 12279 (Po0.001) and 8176 mmHg (Po0.001) after 3 y. We observed a more significant decrease in diastolic blood pressure in female subjects than male subjects as shown in Table 2 . Furthermore, at the end of the follow-up period, we could observe Follow-up of decreased CV risk factors after biliary-intestinal bypass C Lubrano et al that female subjects obtained significant lower systolic and diastolic blood pressure values as compared to male subjects (Table 2) .
In our group, five patients were affected by diabetes mellitus, one patient had IFG, two patients had IGT and nine patients were hyperinsulinemic. After 12 months, glucose and insulin levels were normalised (Figures 3 and 4) .
Additionally, as shown in Figure 3 , fasting glucose levels and glucose levels 120 min after oral glucose load were both significantly reduced, further suggesting an improvement in metabolic control. In fact, insulin values, which were significantly high (30.0720.4 mUI/ml), decreased in a timedependent manner after bypass with a final value of 8.672.9 mUI/ml (Po0.001) after 3 y of follow-up. Final insulin values were significantly higher (Po0.05) in female participants than in male participants (Table 2) . Moreover, as depicted in Figure 4 , insulin levels 120 min after OGTT were 105.5761.5 mUI/ml at baseline but were dramatically influenced by surgery intervention and weight loss reaching a value of 12.076.0 mUI/ml (P40.001) at the end of the follow-up period.
There was no mortality after this type of surgery. All patients experienced transient (3-6 months) hepatic alterations (transaminases and gGT). Diarrhoea, rectal abscesses, anus inflammation or haemorrhoids, always present in this type of surgery, disappeared within 3 months of surgery. No other alterations were observed since mineral and vitamin supplements were taken by all patients during the first period. Postsurgery clinical adverse experiences were as follows: 8.9% seromas, all resolved within 30 days of surgery; 13.3% abdominal hernias, corrected during abdominal plastic intervention, performed 2 y after bypass; and 4.4% gall bladder-jejunum anastomosis fistulae, closed within a few days, without recourse to hospital.
We also observed 2.2% acute renal failure immediately postsurgery, which was resolved with pharmacological therapy. Finally, there was no significant difference in side effects between the sexes.
Discussion
This study demonstrates that biliary-intestinal bypass produced a massive, rapid and permanent weight loss along with a dramatic reduction of obesity-related cardiovascular risk factors. More importantly, all the parameters considered showed a rapid and dramatic decrease soon after surgery without, however, influencing lean mass, but with significant and persistent fat mass modifications after 3 y follow-up.
Central obesity is considered the most important risk factor for CVDs due to the significant metabolic changes that are associated with visceral fat deposition. 4, 28 Indeed, it is well known that obesity is associated with modifications in both lipid and glucose metabolism, with a consequent increase in total cholesterol, triglycerides, glycaemic values as well as coagulation factors. The significant reduction of total cholesterol, already observed after the first month after surgery, suggests a major role for cholesterol malabsorption after the biliary-intestinal bypass since bile is shunted away from the sites of maximal cholesterol absorption such as the duodenum and proximal jejunum. [29] [30] [31] The gradual reduction of triglycerides, on the contrary, seems to be more strictly related to weight loss, as commonly observed during weight reduction induced by hypocaloric diets and after other bariatric surgery interventions. 32, 33 Nevertheless, both parameters, are persistently reduced at the end of the followup period, which also suggests partial correction of nutritional behaviour besides malabsorption induced by surgical procedures. should be used to obtain such information. 37 However, since it was not possible to perform many CT scans or MRIs in these patients, DXA was chosen for the evaluation of body and trunk fat loss. In fact, as previously demonstrated, the risk of developing systemic hypertension is a function of centrally deposited body fat, more than the overall degree of adiposity. 38, 39 Further, DXA was also chosen since it allows evaluating and obtaining information on both lean and fat mass. 25 Indeed, this type of analysis demonstrated that lean mass reduction was less pronounced with respect to fat mass and total body weight, probably due to a suggested hypolipidic, normoglycidic and hyperproteic diet and the increased physical activity performed by the patients. Type II diabetes mellitus is characterised by resistance to insulin action on glucose uptake in peripheral tissues (especially skeletal muscle and adipocytes), by impaired insulin action to inhibit hepatic glucose production and by disregulated insulin secretion. 26 Some authors pointed out the normalisation of insulin secretion and glucose metabolism after surgically induced weight loss. 40 Others showed the beneficial effects of malabsorptive surgery such as biliopancreatic diversion 41 and gastric bypass 42 on glucose metabolism. In the study described herein, we obtained normalisation of glycaemic and insulinemic values in all patients who underwent surgery. Several studies have suggested that reduced glucose tolerance and hyperinsulinism may play a pivotal role in the pathophysiology of hypertension. 43 Additionally, further evidence also indicates that hypertension might be related to obesity, and that the risk of developing arterial hypertension is a function of centrally deposited body fat more than the overall degree of adiposity. 44 These results might explain the successful control of blood pressure values after significant weight loss in these patients. Although Table 2 shows that both male and female patients lose weight, it is interesting to note that female patients lose less adipose tissue (as measured by DXA) in all analysed districts except for trunk fat. Thus, female patients maintained, after weight loss, a BMI between 30 and 34.9 kg/m 2 , while male patients obtained a BMI between 25 and 29.9 kg/m 2 . Additionally fasting insulin levels were significantly higher in female than male patients, most probably because of the difference in total fat loss.
Female patients showed lower blood pressure levels, most probably for the characteristic hormonal milieu: Indeed, CVD is infrequent before menopause; 45 therefore, these results are not related to higher blood pressure levels. In severely obese patients, very low-calorie diet associated with intensive lifestyle education promotes long-term weight loss of approximately 35% after 3-3.5 y. 46 Pharmacological treatment of obesity usually produces weight loss Z15 kg and often substantial weight regain when intervention is discontinued. 14, 15 In comparison with jejunum-ileal bypass, the biliaryintestinal bypass shows several advantages such as absence of severe liver damage interstitial ossalic nephritis and persistent intestinal malabsorption. Additionally, follow-up is easier due to the lack of important side effects such as severe persistent diarrhoea and serious alteration of intestinal microbial flora.
The results presented herein show that biliary-intestinal bypass is effective in achieving a significant and long-term stable weight loss in patients resistant to other nutritional or pharmacological intervention. 14 In conclusion, the biliary-intestinal bypass may represent a valid alternative for the treatment of massive obesity since it induces a significant and stable reduction of weight and many risk factors pertaining to CVDs.
Follow-up of decreased CV risk factors after biliary-intestinal bypass C Lubrano et al
